SK-MEL-31Homo sapiens (Human)Cancer cell line
Also known as: AX-Mel, SKMEL31, SkMel31, SKMel-31, SKMEL-31, Sk-Mel-31
Quick Overview
Human melanoma cell line with known BRAF and NRAS mutations, used in cancer research.
Detailed Summary
Basic Information
| Database ID | CVCL_0600 |
|---|---|
| Species | Homo sapiens (Human) |
Donor Information
| Age | 33 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Cutaneous melanoma |
|---|---|
| Lineage | Skin |
| Subtype | Cutaneous Melanoma |
| OncoTree Code | SKCM |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000640_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | BRAF | p.Val600Glu (c.1799T>A) | Unspecified | - | PubMed=26214590 |
| Gene deletion | PTEN | - | Hemizygous | - | Wistar |
| Gene deletion | CDKN2B | - | Homozygous | - | PubMed=35933914 |
| Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Rosen N., Solit D.B.
Cancer Res. 74:2340-2350(2014).
Functional profiling of live melanoma samples using a novel automated platform.
Schuchter L.M., Clark D.P.
PLoS ONE 7:E52760-E52760(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Wolchok J.D., Houghton A.N., Solit D.B.
Oncogene 31:446-457(2012).
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Guldberg P., Borg A.
Oncogene 26:4738-4748(2007).
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Fountain J.W.
Genes Chromosomes Cancer 22:157-163(1998).
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.
J. Exp. Med. 156:1755-1766(1982).
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
J. Natl. Cancer Inst. 66:1003-1012(1981).
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
Old L.J.
J. Exp. Med. 158:53-65(1983).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice.
Zanzonico P.B., Bigler R.E., Yeh S., Oettgen H.F., Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 84:4200-4204(1987).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
Meyer zum Buschenfelde K.-H.
Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989).
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
Shiku H., Takahashi T., Oettgen H.F., Old L.J.
J. Exp. Med. 144:873-881(1976).
Malignant melanoma. Current status of the search for melanoma-specific antigens.
Houghton A.N., Oettgen H.F., Old L.J.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981).